6-羟基异喹啉-1(2H)-酮 | 252061-78-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 异喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 6-羟基异喹啉-1(2H)-酮
• 英文名称: 6-hydroxyisoquinolin-1(2H)-one
• 英文别名: 6-hydroxy-2H-isoquinolin-1-one
• CAS: 252061-78-2
• 化学式: C₉H₇NO₂
• 分子量: 161.16
• InChiKey: GCJZYOIXXVVQKC-UHFFFAOYSA-N

物化性质

• 沸点：
  506.1±50.0 °C(Predicted)
• 密度：
  1.337±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933790090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  6-羟基异喹啉-1(2H)-酮 在 sodium hydride 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 24.0h， 生成 [6-(4-Cyano-benzyloxy)-1-oxo-1H-isoquinolin-2-yl]-acetic acid tert-butyl ester
  参考文献：
  名称：

  Fused Bicyclic Gly-Asp β-Turn Mimics with Specific Affinity for GPIIb-IIIa

  摘要：

  Disubstituted isoquinolones 2 and 3 have affinity for GPIIb-IIIa and represent leads for further structural evaluation. Structure-activity studies centered on the bicyclic beta-turn mimic contained in these molecules indicated that this moiety could accommodate a variety of modifications. Specifically, monocyclic, 6,5-bicyclic, and 6,7-bicyclic structures provide compounds with affinity for GPIIb-IIIa. Within the 6,6-series, isoquinoline, tetralin, tetralone, and benzopyran nuclei yield potent antagonists that are specific for GPIIb-IIIa. Attachment of the arginine isostere (benzamidine) to the supporting nucleus can be accomplished with an ether or amide linkage, although the latter enhances activity. Several compounds in this series provided measurable blood levels after oral dosing. Conversion of the acid moiety in these molecules to an ester generally provided compounds which gave greater systemic exposure after oral administration. Absolute bioavailabilities in the rat for the ethyl ester prodrug derivatives of the tetralin, tetralone, and benzopyran analogues of 3 were 28%, 23%, and 24%, respectively.

  DOI：

  10.1021/jm990365y
• 作为产物：
  描述：

  6-甲氧基异喹啉-1(2H)-酮 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成 6-羟基异喹啉-1(2H)-酮
  参考文献：
  名称：

  New substituted isoquinoline and isoquinolinone derivatives

  摘要：

  这项发明涉及用于治疗和/或预防与Rho激酶和/或Rho激酶介导的肌球蛋白轻链磷酸酶磷酸化相关疾病的公式(I)的6-取代异喹啉和异喹啉衍生物，以及含有这类化合物的组合物。

  公开号：

  US20100056566A1

文献信息

• Divergent Synthesis of Isoquinolone and Isocoumarin Derivatives by the Annulation of Benzoic Acid with <i>N</i>-Vinyl Amide
  作者：Rui Sun、Xiao Yang、Qianggen Li、Ke Xu、Juan Tang、Xueli Zheng、Maolin Yuan、Haiyan Fu、Ruixiang Li、Hua Chen

  DOI：10.1021/acs.orglett.9b03638

  日期：2019.12.6

  A simple and efficient method for the synthesis of isoquinolone and isocoumarin derivatives is reported. The method for the first time provides a one-step divergent synthesis of important isoquinolone and isocoumarin skeletons from benzoic acid by switching the coupling partners. In addition, a reliable mechanism has been proposed on the basis of experimental investigations, including kinetic isotope

  报道了一种简单有效的合成异喹诺酮和异香豆素衍生物的方法。该方法首次通过切换偶联伙伴，从苯甲酸一步一步地合成了重要的异喹诺酮和异香豆素骨架。此外，在实验研究的基础上，提出了一种可靠的机制，包括动力学同位素效应实验，13C标记实验，时间跟踪实验和竞争实验，以及DFT计算研究。
• RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF
  申请人：BEIJING TIDE PHARMACEUTICAL CO., LTD.

  公开号：US20220002266A1

  公开（公告）日：2022-01-06

  A Rho-associated protein kinase (ROCK) inhibitor represented by formula (I), a pharmaceutical composition comprising same, and a use thereof for preventing or treating ROCK-mediated diseases.

  一个由公式(I)表示的Rho相关蛋白激酶(ROCK)抑制剂，包含该抑制剂的药物组合物，以及用于预防或治疗ROCK介导的疾病的应用。
• Isoquinoline derivatives
  申请人：Ray Christopher Peter

  公开号：US20070135479A1

  公开（公告）日：2007-06-14

  The invention relates to isoquinoline derivatives having the general Formula I wherein X is O, S or NH; Y is OH or NH 2 ; m is 0, 1 or 2; n is 1 or 2; R 1 is H, when Y is NH 2 ; or R. is H, (C 1-4 )alkyl or halogen, when Y is OH; R 2 and R 3 are independently H, (C 1-4 )alkyl or halogen; R is H or (C 1-6 )alkyl, optionally substituted with OH, (C 1-4 )-alkyloxy, (C 1-4 )alkyloxycarbonyl, (C 3-7 )cycloalkyl, which may optionally comprise a heteroatom selected from O and S, (C 6-10 )aryl, (C 6-10 )aryloxy or a 5- or 6-membered heteroaryl group comprising 1-3 heteroatoms independently selected from O, N and S, each aryl or heteroaryl group being optionally substituted with 1-3 substituents independently selected from (C 1-4 )alkyl, (C 1-4 )alkyloxy, (C 1-4 )alkylsulfonyl and halogen; or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same as well as to the use of the isoquinoline derivatives in the treatment of ROCK-I related disorders such as hypertension, atherosclerosis and glaucoma.

  本发明涉及具有通式I的异喹啉衍生物，其中X为O、S或NH；Y为OH或NH2；m为0、1或2；n为1或2；当Y为NH2时，R1为H；或当Y为OH时，R为H、(C1-4)烷基或卤素；R2和R3独立地为H、(C1-4)烷基或卤素；R为H或(C1-6)烷基，可选地取代为OH、(C1-4)烷氧基、(C1-4)烷氧羰基、(C3-7)环烷基，可选地包含从O和S中选择的杂原子，(C6-10)芳基、(C6-10)芳氧基或包含1-3个从O、N和S中独立选择的杂原子的5-或6成员杂芳基，每个芳基或杂芳基可选地取代为1-3个从(C1-4)烷基、(C1-4)烷氧基、(C1-4)烷基磺酰基和卤素中独立选择的取代基；或其药学上可接受的盐，以及包含相同的药物组合物，以及在治疗ROCK-I相关疾病如高血压、动脉粥样硬化和青光眼中使用异喹啉衍生物。
• [EN] SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS<br/>[FR] ISOQUINOLINES ET ISOQUINOLINONES SUBSTITUÉES UTILISÉES COMME INHIBITEURS DE RHO-KINASE
  申请人：SANOFI AVENTIS

  公开号：WO2009156100A1

  公开（公告）日：2009-12-30

  The invention relates to substituted isoquinoline and isoquinolinones of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

  该发明涉及用于治疗和/或预防与Rho激酶和/或Rho激酶介导的肌球蛋白轻链磷酸酶磷酸化相关疾病的配方(I)的取代异喹啉和异喹啉酮，以及含有这种化合物的组合物。
• 一种作为甲状腺激素β受体激动剂的化合物及其用途
  申请人：广东东阳光药业有限公司

  公开号：CN114195764A

  公开（公告）日：2022-03-18

  本发明涉及一种作为甲状腺激素β受体激动剂的化合物及其用途，进一步涉及包含所述化合物的药物组合物。本发明所述的化合物或药物组合物可以用于制备预防、治疗或减轻由甲状腺激素β受体调节的疾病的药物，尤其用于制备治疗非酒精性脂肪性肝病的药物。